- Zymeworks Inc. recently reported first-quarter 2026 results showing a wider net loss of US$44.16 million and a basic loss per share of US$0.59 as lower milestone revenue weighed on earnings.
- At the same time, the company underscored its upcoming August 2026 FDA Priority Review decision for zanidatamab and a cash runway it expects to extend beyond 2028, supported by royalty financing and share repurchases.
- Now we will examine how the widened quarterly loss alongside the imminent zanidatamab FDA decision reshapes Zymeworks’ broader investment narrative.
The latest GPUs need a type of rare earth metal called Terbium and there are only 33 companies in the world exploring or producing it. Find the list for free.
Zymeworks Investment Narrative Recap
To own Zymeworks, you have to believe its partnered HER2 asset zanidatamab and early ADC pipeline can eventually justify today’s losses and lumpy collaboration revenue. The widened Q1 2026 net loss does not appear to change the key near term catalyst, which remains the August 25, 2026 FDA Priority Review decision, but it does keep funding risk and dependence on milestone timing front and center for the biggest current downside.
Against this backdrop, Zymeworks’ move to monetize 30% of future zanidatamab royalties via a US$250 million non recourse loan, leaving cash and marketable securities at about US$403.8 million, is highly relevant. It helps underpin management’s view of a cash runway beyond 2028 around the same time the zanidatamab PDUFA decision could potentially trigger up to US$265 million in additional milestone payments and reshape how investors weigh near term risk versus longer term optionality.
However, beneath the extended cash runway and pending FDA decision, investors should still be aware of how dependent Zymeworks remains on partner milestones and royalty timing...
Read the full narrative on Zymeworks (it's free!)
Zymeworks' narrative projects $184.8 million revenue and $23.6 million earnings by 2029.
Uncover how Zymeworks' forecasts yield a $40.08 fair value, a 51% upside to its current price.
Exploring Other Perspectives
Before this earnings miss, the most cautious analysts were modeling revenue shrinking 3.7 percent a year and no profitability by 2029, so your view on partner risks and milestone timing could look very different once you factor in the new Q1 loss and upcoming zanidatamab decision.
Explore 2 other fair value estimates on Zymeworks - why the stock might be worth just $40.08!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Zymeworks research is our analysis highlighting 3 key rewards that could impact your investment decision.
- Our free Zymeworks research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zymeworks' overall financial health at a glance.
Seeking Other Investments?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
- Capitalize on the AI infrastructure supercycle with our selection of the 40 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com